Fagan AM - Search Results

1

Comparative Analysis of Alzheimer's Disease Cerebrospinal Fluid Biomarkers Measurement by Multiplex SOMAscan Platform and Immunoassay-Based Approach.

Timsina J, Gomez-Fonseca D, Wang L, Do A, Western D, Alvarez I, Aguilar M, Pastor P, Henson RL, Herries E, Xiong C, Schindler SE, Fagan AM, Bateman RJ, Farlow M, Morris JC, Perrin RJ, Moulder K, Hassenstab J, Vöglein J, Chhatwal J, Mori H; Alzheimer’s Disease Neuroimaging Initiative; Dominantly Inherited Alzheimer Network Consortia; Sung YJ, Cruchaga C. Timsina J, et al. Among authors: fagan am. J Alzheimers Dis. 2022;89(1):193-207. doi: 10.3233/JAD-220399. J Alzheimers Dis. 2022. PMID: 35871346 Free PMC article.

2

Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia.

Han X, Fagan AM, Cheng H, Morris JC, Xiong C, Holtzman DM. Han X, et al. Among authors: fagan am. Ann Neurol. 2003 Jul;54(1):115-9. doi: 10.1002/ana.10618. Ann Neurol. 2003. PMID: 12838527

3

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM. Fagan AM, et al. Ann Neurol. 2006 Mar;59(3):512-9. doi: 10.1002/ana.20730. Ann Neurol. 2006. PMID: 16372280

4

The search for antecedent biomarkers of Alzheimer's disease.

Fagan AM, Csernansky CA, Morris JC, Holtzman DM. Fagan AM, et al. J Alzheimers Dis. 2005 Mar;8(4):347-58. doi: 10.3233/jad-2005-8404. J Alzheimers Dis. 2005. PMID: 16556966 Review.

5

Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia.

Csernansky JG, Dong H, Fagan AM, Wang L, Xiong C, Holtzman DM, Morris JC. Csernansky JG, et al. Among authors: fagan am. Am J Psychiatry. 2006 Dec;163(12):2164-9. doi: 10.1176/ajp.2006.163.12.2164. Am J Psychiatry. 2006. PMID: 17151169 Free PMC article.

6

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Fagan AM, et al. Arch Neurol. 2007 Mar;64(3):343-9. doi: 10.1001/archneur.64.3.noc60123. Epub 2007 Jan 8. Arch Neurol. 2007. PMID: 17210801

7

Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation.

Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, Fagan AM, Holtzman DM, Morris JC, Goate AM. Kauwe JS, et al. Among authors: fagan am. Ann Neurol. 2007 May;61(5):446-53. doi: 10.1002/ana.21099. Ann Neurol. 2007. PMID: 17366635

8

Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition.

Kauwe JS, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P, Galimberti D, Scarpini E, Morris JC, Fagan AM, Holtzman DM, Goate AM. Kauwe JS, et al. Among authors: fagan am. Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8050-4. doi: 10.1073/pnas.0801227105. Epub 2008 Jun 9. Proc Natl Acad Sci U S A. 2008. PMID: 18541914 Free PMC article.

9

Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta.

Kauwe JS, Wang J, Mayo K, Morris JC, Fagan AM, Holtzman DM, Goate AM. Kauwe JS, et al. Among authors: fagan am. Neurogenetics. 2009 Feb;10(1):13-7. doi: 10.1007/s10048-008-0150-4. Epub 2008 Sep 24. Neurogenetics. 2009. PMID: 18813964 Free PMC article.

10

Biomarkers of Alzheimer's disease.

Craig-Schapiro R, Fagan AM, Holtzman DM. Craig-Schapiro R, et al. Among authors: fagan am. Neurobiol Dis. 2009 Aug;35(2):128-40. doi: 10.1016/j.nbd.2008.10.003. Epub 2008 Oct 28. Neurobiol Dis. 2009. PMID: 19010417 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

327 results

Search Page